RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the second quarter ended June 30, 2015.
“During the second quarter of 2015, we made substantial gains in advancing our Phase 3 study of oral Pyridorin to treat diabetic nephropathy,” said Chief Executive Officer Pierre Legault.
Help employers find you! Check out all the jobs and post your resume.
